Want to join the conversation?
Segment-wise, 1Q16 revenue from $A's Life Sciences and Applied Markets Group (LSAG) declined 4% YoverY to $526MM, driven by the softness in the applied markets. Revenue from the CrossLab Group (ACG) grew 4% YoverY to $344MM, while Diagnostics and Genomics Group (DGG) increased 7% to $158MM.
$WBA is yet to receive US anti-trust clearance for its Rite Aid acquisition. The deadline for the deal expires on January 27.
$BMY plunge 7.2%. No credits to the non-acceleration of approval for lung cancer combination treatment.
Well this is big! I don’t know if it’s someone’s monopoly or genuine excitement, but either way, $CSX is up 23% after market closed. I heard some activist investor is going to blow big money into CSX Corp. Anyone mind explaining?